Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy
To compare and evaluate the efficacy and safety of Liporaxel速 solution (oral paclitaxel) and Taxol速 (IV paclitaxel) on recurrent or metastatic breast cancer.
Recurrent or Metastatic Breast Cancer
DRUG: Oral paclitaxel|DRUG: Paclitaxel injection
[Phase II] Objective Response Rate (ORR), Objective Response Rate (ORR) is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (v.1.1) criteria., Participants will be followed every 6 weeks until progression, an expected average of 9 months.|[Phase III] Progression Free Survival (PFS), Progression Free Survival (PFS) is defined as the time from date of randomization until the date of first documented progression or death, From date of randomization, assessed up to 18 months.
[Phase II] Progression Free Survival (PFS), Progression Free Survival (PFS) is defined as the time from date of randomization until the date of first documented progression or death, From date of randomization, assessed up to 18 months.|[Phase III] Objective Response Rate (ORR), Objective Response Rate (ORR) is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (v.1.1) criteria., Participants will be followed every 6 weeks until progression, an expected average of 9 months.|[Phase II&III] Overall Survival(OS), Overall survival(OS) is defined as the time from the date of inclusion to the date of death, regardless of the cause of death., Until 6 months after the last participant is enrolled, assessed minimum to 18 months.|[Phase II&III] Time to Treatment Failure(TTF), TTF is defined as the time from the randomization date to the date of discontinuation of treatment, regardless of the cause., through study completion, an expected average of 4.5 year.|[Phase II&III] Disease Control Rate(DCR), DCR is defined as the percentage of subjects who were evaluated for complete response(CR), partial response(PR), and stable disease(SD) as the best response among from randomization to End of treatment(EOT)., through study completion, an expected average of 4.5 year.|[Phase II&III] Quality of life(QoL), To evaluate changes versus baseline using the EQ-5D., C1D1, C2D1, C4D1, C7D1, C10D1 (each cycle is 28 days) and study completion, up to 18 months.|Incidence of Treatment-Emergent Adverse Events [Safety], Number and Description of Adverse Events, Up to 28 days after last investigational product administraion.
To compare and evaluate the efficacy and safety of Liporaxel速 solution (oral paclitaxel) and Taxol速 (IV paclitaxel) on recurrent or metastatic breast cancer.